Patents by Inventor Philippe Vincent Hermand

Philippe Vincent Hermand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE
    Publication number: 20220354941
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 10, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
  • Pneumococcal capsular saccharide conjugate vaccine
    Patent number: 11400147
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: August 2, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Immunogenic Composition
    Publication number: 20200405841
    Abstract: The present invention relates to the field of immunogenic compositions and vaccines and the use of such compositions in medicine. More particularly, it relates to immunogenic fragments of UspA2 comprising an epitope and immunogenic compositions and vaccines comprising said fragments, for use in preventing or treating an infection, disease or condition caused by heterologous strain(s) of Moraxella catarrhalis. The invention further relates to immunogenic compositions and vaccines comprising an immunogenic fragment wherein said fragment comprises an epitope with cross-bactericidal activity.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 31, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nathalie Isabelle Devos, Vincent DEWAR, Philippe Vincent HERMAND, Silvia ROSSI PACCANI, Vincent WEYNANTS
  • Vaccine
    Patent number: 10646564
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 12, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Vaccine
    Publication number: 20190262447
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Application
    Filed: February 21, 2019
    Publication date: August 29, 2019
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Vaccine comprising capsular polysaccharide conjugates
    Patent number: 10279033
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: May 7, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES
    Publication number: 20180250389
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Application
    Filed: January 5, 2016
    Publication date: September 6, 2018
    Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
  • PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE
    Publication number: 20180207262
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
  • Pneumoccal polysacchride conjugate vaccine
    Patent number: 9884113
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: February 6, 2018
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Vaccine comprising capsular polysaccharide conjugates
    Patent number: 9610339
    Abstract: The present invention relates to an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Methods of making and uses thereof are also described.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: April 4, 2017
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garçon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Vaccine comprising capsular polysaccharide conjugates
    Patent number: 9610340
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: April 4, 2017
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garçon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES
    Publication number: 20160243219
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Application
    Filed: January 5, 2016
    Publication date: August 25, 2016
    Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
  • Treatment of streptococcal infections
    Patent number: 9314518
    Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: April 19, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Denoel, Philippe Vincent Hermand, Steve Labbe, Jan Poolman, Stephane Rioux
  • PNEUMOCCAL POLYSACCHRIDE CONJUGATE VACCINE
    Publication number: 20150265702
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Application
    Filed: June 3, 2015
    Publication date: September 24, 2015
    Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
  • Pneumococcal polysaccharide conjugate vaccine
    Patent number: 9107872
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: August 18, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Pneumococcal capsular saccharide conjugate vaccine
    Publication number: 20150190521
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
    Type: Application
    Filed: August 14, 2014
    Publication date: July 9, 2015
    Inventors: Ralph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
  • TREATMENT OF STREPTOCOCCAL INFECTIONS
    Publication number: 20140205634
    Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 24, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe DENOEL, Philippe Vincent HERMAND, Steve LABBE, Jan POOLMAN, Stephane RIOUX
  • TREATMENT OF STREPTOCOCCAL INFECTIONS
    Publication number: 20120328659
    Abstract: Immunogenic compositions and methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Application
    Filed: March 8, 2011
    Publication date: December 27, 2012
    Inventors: Philippe Denoel, Philippe Vincent Hermand, Steve Labbe, Jan Poolman, Stephane Rioux
  • VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES
    Publication number: 20100239604
    Abstract: The present invention relates to an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Methods of making and uses thereof are also described.
    Type: Application
    Filed: June 24, 2008
    Publication date: September 23, 2010
    Inventors: Ralph Leon Biemans, Philippe Vincent Hermand, Jan Poolman
  • VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES
    Publication number: 20100209450
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid. Methods of making and uses thereof are also described.
    Type: Application
    Filed: June 24, 2008
    Publication date: August 19, 2010
    Inventors: Ralph Leon Biemans, Philippe Vincent Hermand, Jan Poolman